An observational study in Transthyretin Cardiac Amyloidosis, sponsored by Idoven 1903 S.L.. Recruiting at 8 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by Idoven 1903 S.L. · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 49 studies in Amyloidosis with a site in Spain — 14 open to participants now, 20 under way, 8 of them phase 3. Amyloidosis · Spain.
Among the 49 studies in Amyloidosis with a site in Spain, this one is the 3rd largest by planned enrollment of the 12 observational ones that give a count, is one of 4 that started in 2025, is one of 12 observational ones, reaches primary completion later than 5 of the 19 other live ones, and was the 45th registered.
290 studies on the registry are indexed under Amyloidosis; 92 are open to participants now.
Browse Amyloidosis studies →14 of the 49 studies in Amyloidosis with a site in Spain are open now. Recruiting first, the newest first:
Eidos Therapeutics, a BridgeBio company · Sites in Spain, United States, Singapore
Ages 18–80
Alnylam Pharmaceuticals · Sites in Spain, United States, Argentina and 19 more countries
Ages 18–85
Alnylam Pharmaceuticals · Sites in Spain, United States, Argentina and 33 more countries
Ages 18–85
Eidos Therapeutics, a BridgeBio company · Sites in Spain, United States, Argentina and 21 more countries
Ages 18–75
Consorci Sanitari de l'Alt Penedès i Garraf · Sites in Spain
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 70 Amyloidosis studies recruiting now, 43 (61%) set no upper age limit and 3 (4%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
49 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 12 · Phase 3 23 · Phase 4 1
First in 2001; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 2,200 is above the median of 190 across 83 observational studies indexed under Amyloidosis.
Median enrollment 173 across the 37 interventional studies, 450 across the 12 observational. Of the 27 that completed or were terminated, 17 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
44 of 49 have an industry lead sponsor. The 10 most frequent:
Idoven 1903 S.L. is the lead sponsor of 7 studies on the registry; 5 are open to participants now.
Idoven 1903 S.L. has 1 study filed under Amyloidosis — fewer than ten, so there is no comparison to draw.
3 of the studies in Amyloidosis with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06978660Idoven 1903 S.L.Multicenter Study for the Validation of an AI-based ECG Platform for Early Cardiac Amyloidosis Diagnosis | 2026-12 |
| NCT05652335Janssen Research & Development, LLCA Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis | 2027-04-19 |
| NCT06527521Consorci Sanitari de l'Alt Penedès i GarrafPrevalence of Amyloidosis in Trauma Patients | 2027-08 |
Add all 3 to your calendar (.ics) → With an account.
Among the 49 studies in Amyloidosis with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
CONCERTO is a retrospective, observational, multicentric and single-arm study to perform an external validation of the cloud-based and AI-powered electrocardiogram (ECG) analysis platform, named Willem™, to detect Transthyretin cardiac amyloidosis (ATTR-CA). Thus, this study will assess Willem™ ability to distinguish between truly diagnosed ATTR-CA patients and confirmed non-ATTR-CA patients from ECG data.
Transthyretin cardiac amyloidosis (ATTR-CA) is an infiltrative cardiomyopathy affecting cardiac health. Results from clinical trials have shown the importance of early diagnosis to improve outcomes and maximize treatment efficacy.
An electrocardiogram (ECG) is the most commonly performed cardiac diagnostic procedure, providing a large amount of information that can reflect cardiac structure and physiology. In this regard, ECG could be an ideal screening tool for ATTR-CA given its wide use, non-invasive nature, low cost and high sensitivity to reflect ATTR-CA abnormalities.
The CE-marked Willem™ ECG Analysis platform has already shown its capability to process ECG data to detect cardiac patterns and arrythmias. This retrospective, observational, multicentric and single-arm study aims to expand the capabilities of the Willem™ ECG Analysis platform, in this case to detect ATTR-CA from ECG analysis.
Subjects with a suspected or confirmed diagnosis of ATTR-CA
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adult patients with confirmed diagnosis of ATTR-CA
Adult subjects suspected of ATTR-CA, but finally confirmed not to have ATTR-CA
Device performance
Assessment of Willem ability to distinguish between confirmed diagnosed ATTR-CA patients and subjects with no ATTR-CA diagnosis from ECG data of sufficient quality. The diagnostic performance metrics will be accuracy, sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and F1-score.
Time frame: Baseline (closest clinical assessment to ATTR-CA diagnosis)
Device performance with sub-optimal ECG data quality
Assessment of Willem ability to distinguish between confirmed diagnosed ATTR-CA patients and subjects with no ATTR-CA diagnosis from ECG data which does not meet the minimum pre-specified quality requirements. The diagnostic performance metrics will be accuracy, sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and F1-score.
Time frame: Baseline (closest clinical assessment to ATTR-CA diagnosis)
Not enrolling at this site.
Not enrolling at this site.
Not enrolling at this site.
Not enrolling at this site.
Plan to share: No
No publications or documents are linked to this record.
Started May 2025 (actual). Primary completion is estimated for Dec 2026, 19 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 4, 2026: primary completion Sep 2026 → Dec 2026 and completion Dec 2026 → Jan 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Idoven 1903 S.L.